Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2015 | Subgroup analysis of the PANORAMA 1 trial of panobinostat for multiple myeloma

Jesús San Miguel • 12 Jun 2015
EHA 2015
Multiple Myeloma Panobinostat

At the 20th Congress of the European Hematology Association (EHA), Jesús F. San Miguel, MD, of the Clínica Universidad de Navarra, Navarra, Spain, discusses the results of a predefined subgroup analysis of the PANORAMA 1 trial, which evaluated the histone deacetylase inhibitor, panobinostat, plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma who received prior bortezomib and lenalidomide or thalidomide.

More from Jesús San Miguel

Key myeloma highlights from EHA 2023
Enrique Ocio et al. • 9 Jun 2023
1:11
The future of myeloma therapy and where the treatment landscape is moving
Jesús San Miguel • 13 May 2022
1:21
The value of sustained MRD negativity in MM
Jesús San Miguel • 13 May 2022
1:21
MRD evaluation: how, when and for which goal?
Jesús San Miguel • 13 May 2022

Related Videos

0:59
Looking forward to COMy 2024: celebrating 10 years
Mohamad Mohty • 17 Apr 2024
0:57
Overcoming barriers to treating older patients with myeloma
Sergio Giralt • 16 Apr 2024
1:01
The potentially curative role of CAR-T therapy in myeloma
Sergio Giralt • 16 Apr 2024
1:45
Expanded approval of cilta-cel in myeloma: the value of bringing CAR-T cells into earlier lines
Monika Engelhardt • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals